Citations should be made in the following way: Authors. Title. Eur Respir J 2014; 44: Suppl. 58, abstract number.
Citations should be made in the following way: Authors. Title. Eur Respir J 2014; 44: Suppl. 58, abstract number.
Current therapeutic options in stage I non-small cell lung cancer (NSCLC)
Symposium Chairs: P. Van Schil (Antwerp, Belgium), A.P. Meert (Brussels, Belgium)
Aims: Despite a widespread belief that early stage lung cancer does not pose major problems in practice, minimally invasive procedures are increasingly being used, either in the staging of the mediastinum (EBUS and VAMLA) or for curative intent (VATS procedures and radiofrequency ablation). A balanced approach, the primary goal of which is the oncological benefit, is needed. The aim of the symposium is to describe the advantages and limitations of these procedures compared with the usual diagnostic and therapeutic approaches that are used in this stage of lung cancer.